Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer

This review focuses on studies of coordination and organometallic compounds as potential chemotherapeutics against triple negative breast cancer (TNBC) which has one of the poorest prognoses and worst survival rates from all breast cancer types. At present, chemotherapy is still the standard of care for TNBC since only one type of targeted therapy has been recently developed. References for metal-based compounds studied in TNBC cell lines will be listed, and those of metal-specific reviews, but a detailed overview will also be provided on compounds studied in vivo (mostly in mice models) and those compounds for which some preliminary mechanistic data was obtained (in TNBC cell lines and tumors) and/or for which bioactive ligands have been used. The main goal of this review is to highlight the most promising metal-based compounds with potential as chemotherapeutic agents in TNBC.

Automated summary

This review focuses on the potential of coordination and organometallic compounds as chemotherapeutics for triple negative breast cancer (TNBC), which has poor prognoses and survival rates compared to other types of breast cancer. The review lists references for metal-based compounds studied in TNBC cell lines and in vivo, and aims to highlight the most promising metal-based compounds with potential as chemotherapeutic agents for TNBC.